Real-life clinical practice of onabotulinum toxin A intravesical injections for overactive bladder wet: an Italian consensus statement

A Giannantoni, A Carbone, Roberto Carone, Mauro Cervigni, G Del Popolo, E. Finazzi Agrò, G Giocoli Nacci, Giovanni Palleschi, S Salvatore, M Spinelli, Andrea Tubaro

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: We developed a consensus on best practice in the real-life management of patients with overactive bladder (OAB) with onabotulinumtoxin A (Onabot/A). Methods: In March 2015, an interdisciplinary conference was convened. Eleven panelists were invited to review the literature, to present their personal experience and to respond to a number of questions from: “when do we propose Onabot/A treatment” to “when do you decide to re-inject a patient?” A summary of findings of the meeting was provided to all panelists for review and approval. Results: The following statements were agreed. Refractory OAB can be defined based on lack of adherence to first- and second-line treatments for OAB regardless of the underlying cause. Onabot/A treatment can be proposed to refractory OAB patients provided they are willing to perform intermittent catheterization if needed. Before treatment, uroflowmetry with post-void residual evaluation is needed to rule out voiding dysfunction, while urodynamics should be done in cases of complicated OAB wet. Urinary tract infection should be ruled out or treated before the injection. The injection can be performed in the endoscopy room, in an out-patient basis, with local anesthesia. Antibiotic prophylaxis should be initiated with oral drugs. A first follow-up visit should be planned 10–15 days after treatment and residual urine checked. Retreatment can be decided on patients’ request, when symptoms worsen. Conclusions: This consensus document provides a guide for the management of refractory OAB patients with Onabot/A in real life. A number of questions about the effectiveness of Onabot/A in real life remain open. © 2016 Springer-Verlag Berlin Heidelberg
Original languageEnglish
Pages (from-to)299-306
Number of pages8
JournalWorld Journal of Urology
Volume35
Issue number2
DOIs
Publication statusPublished - 2017

Fingerprint

Intravesical Administration
Overactive Urinary Bladder
Therapeutics
Injections
Retreatment
Antibiotic Prophylaxis
Urodynamics
Berlin
Local Anesthesia
Practice Guidelines
Urinary Tract Infections
Catheterization
Endoscopy
onabotulinumtoxinA
Outpatients
Urine
Pharmaceutical Preparations

Cite this

Giannantoni, A., Carbone, A., Carone, R., Cervigni, M., Del Popolo, G., Finazzi Agrò, E., ... Tubaro, A. (2017). Real-life clinical practice of onabotulinum toxin A intravesical injections for overactive bladder wet: an Italian consensus statement. World Journal of Urology, 35(2), 299-306. https://doi.org/10.1007/s00345-016-1847-x

Real-life clinical practice of onabotulinum toxin A intravesical injections for overactive bladder wet: an Italian consensus statement. / Giannantoni, A; Carbone, A; Carone, Roberto; Cervigni, Mauro; Del Popolo, G; Finazzi Agrò, E.; Giocoli Nacci, G; Palleschi, Giovanni; Salvatore, S; Spinelli, M; Tubaro, Andrea.

In: World Journal of Urology, Vol. 35, No. 2, 2017, p. 299-306.

Research output: Contribution to journalArticle

Giannantoni, A, Carbone, A, Carone, R, Cervigni, M, Del Popolo, G, Finazzi Agrò, E, Giocoli Nacci, G, Palleschi, G, Salvatore, S, Spinelli, M & Tubaro, A 2017, 'Real-life clinical practice of onabotulinum toxin A intravesical injections for overactive bladder wet: an Italian consensus statement', World Journal of Urology, vol. 35, no. 2, pp. 299-306. https://doi.org/10.1007/s00345-016-1847-x
Giannantoni, A ; Carbone, A ; Carone, Roberto ; Cervigni, Mauro ; Del Popolo, G ; Finazzi Agrò, E. ; Giocoli Nacci, G ; Palleschi, Giovanni ; Salvatore, S ; Spinelli, M ; Tubaro, Andrea. / Real-life clinical practice of onabotulinum toxin A intravesical injections for overactive bladder wet: an Italian consensus statement. In: World Journal of Urology. 2017 ; Vol. 35, No. 2. pp. 299-306.
@article{c1a3ae86d806460a834cb3edae507323,
title = "Real-life clinical practice of onabotulinum toxin A intravesical injections for overactive bladder wet: an Italian consensus statement",
abstract = "Purpose: We developed a consensus on best practice in the real-life management of patients with overactive bladder (OAB) with onabotulinumtoxin A (Onabot/A). Methods: In March 2015, an interdisciplinary conference was convened. Eleven panelists were invited to review the literature, to present their personal experience and to respond to a number of questions from: “when do we propose Onabot/A treatment” to “when do you decide to re-inject a patient?” A summary of findings of the meeting was provided to all panelists for review and approval. Results: The following statements were agreed. Refractory OAB can be defined based on lack of adherence to first- and second-line treatments for OAB regardless of the underlying cause. Onabot/A treatment can be proposed to refractory OAB patients provided they are willing to perform intermittent catheterization if needed. Before treatment, uroflowmetry with post-void residual evaluation is needed to rule out voiding dysfunction, while urodynamics should be done in cases of complicated OAB wet. Urinary tract infection should be ruled out or treated before the injection. The injection can be performed in the endoscopy room, in an out-patient basis, with local anesthesia. Antibiotic prophylaxis should be initiated with oral drugs. A first follow-up visit should be planned 10–15 days after treatment and residual urine checked. Retreatment can be decided on patients’ request, when symptoms worsen. Conclusions: This consensus document provides a guide for the management of refractory OAB patients with Onabot/A in real life. A number of questions about the effectiveness of Onabot/A in real life remain open. {\circledC} 2016 Springer-Verlag Berlin Heidelberg",
author = "A Giannantoni and A Carbone and Roberto Carone and Mauro Cervigni and {Del Popolo}, G and {Finazzi Agr{\`o}}, E. and {Giocoli Nacci}, G and Giovanni Palleschi and S Salvatore and M Spinelli and Andrea Tubaro",
year = "2017",
doi = "10.1007/s00345-016-1847-x",
language = "English",
volume = "35",
pages = "299--306",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Real-life clinical practice of onabotulinum toxin A intravesical injections for overactive bladder wet: an Italian consensus statement

AU - Giannantoni, A

AU - Carbone, A

AU - Carone, Roberto

AU - Cervigni, Mauro

AU - Del Popolo, G

AU - Finazzi Agrò, E.

AU - Giocoli Nacci, G

AU - Palleschi, Giovanni

AU - Salvatore, S

AU - Spinelli, M

AU - Tubaro, Andrea

PY - 2017

Y1 - 2017

N2 - Purpose: We developed a consensus on best practice in the real-life management of patients with overactive bladder (OAB) with onabotulinumtoxin A (Onabot/A). Methods: In March 2015, an interdisciplinary conference was convened. Eleven panelists were invited to review the literature, to present their personal experience and to respond to a number of questions from: “when do we propose Onabot/A treatment” to “when do you decide to re-inject a patient?” A summary of findings of the meeting was provided to all panelists for review and approval. Results: The following statements were agreed. Refractory OAB can be defined based on lack of adherence to first- and second-line treatments for OAB regardless of the underlying cause. Onabot/A treatment can be proposed to refractory OAB patients provided they are willing to perform intermittent catheterization if needed. Before treatment, uroflowmetry with post-void residual evaluation is needed to rule out voiding dysfunction, while urodynamics should be done in cases of complicated OAB wet. Urinary tract infection should be ruled out or treated before the injection. The injection can be performed in the endoscopy room, in an out-patient basis, with local anesthesia. Antibiotic prophylaxis should be initiated with oral drugs. A first follow-up visit should be planned 10–15 days after treatment and residual urine checked. Retreatment can be decided on patients’ request, when symptoms worsen. Conclusions: This consensus document provides a guide for the management of refractory OAB patients with Onabot/A in real life. A number of questions about the effectiveness of Onabot/A in real life remain open. © 2016 Springer-Verlag Berlin Heidelberg

AB - Purpose: We developed a consensus on best practice in the real-life management of patients with overactive bladder (OAB) with onabotulinumtoxin A (Onabot/A). Methods: In March 2015, an interdisciplinary conference was convened. Eleven panelists were invited to review the literature, to present their personal experience and to respond to a number of questions from: “when do we propose Onabot/A treatment” to “when do you decide to re-inject a patient?” A summary of findings of the meeting was provided to all panelists for review and approval. Results: The following statements were agreed. Refractory OAB can be defined based on lack of adherence to first- and second-line treatments for OAB regardless of the underlying cause. Onabot/A treatment can be proposed to refractory OAB patients provided they are willing to perform intermittent catheterization if needed. Before treatment, uroflowmetry with post-void residual evaluation is needed to rule out voiding dysfunction, while urodynamics should be done in cases of complicated OAB wet. Urinary tract infection should be ruled out or treated before the injection. The injection can be performed in the endoscopy room, in an out-patient basis, with local anesthesia. Antibiotic prophylaxis should be initiated with oral drugs. A first follow-up visit should be planned 10–15 days after treatment and residual urine checked. Retreatment can be decided on patients’ request, when symptoms worsen. Conclusions: This consensus document provides a guide for the management of refractory OAB patients with Onabot/A in real life. A number of questions about the effectiveness of Onabot/A in real life remain open. © 2016 Springer-Verlag Berlin Heidelberg

U2 - 10.1007/s00345-016-1847-x

DO - 10.1007/s00345-016-1847-x

M3 - Article

VL - 35

SP - 299

EP - 306

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 2

ER -